The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
April 19th 2024
Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases
FDA Updates Hepatitis C Drug Labeling to Include New Clinical Data
August 8th 2018The revised labeling for glecaprevir and pibrentasvir (Mavyret) includes data from clinical trials on the safety and efficacy of the treatment for HIV-1 coinfected patients and liver and kidney transplant recipients.
Read More